An update from Cocrystal Pharma (COCP) is now available.
Cocrystal Pharma, Inc. recently shared exciting news about their CC-42344 product candidate, which shows promise as an antiviral treatment for both pandemic and seasonal influenza A. This update could be a game-changer for investors looking for potential growth opportunities in the biopharmaceutical sector.
Learn more about COCP stock on TipRanks’ Stock Analysis page.